🇺🇸 FDA
Patent

US 9506058

Compositions for treating muscular dystrophy

granted A61KA61K31/7125A61P

Quick answer

US patent 9506058 (Compositions for treating muscular dystrophy) held by Sarepta Therapeutics, Inc. expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sarepta Therapeutics, Inc.
Grant date
Tue Nov 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
29
CPC classes
A61K, A61K31/7125, A61P, A61P1/00, A61P21/00